- Market Capitalization, $K 455,574
- Shares Outstanding, K 42,577
- Annual Sales, $ 0 K
- Annual Income, $ -71,740 K
- 60-Month Beta 2.29
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 2.34
|Period||Period Low||Period High||Performance|
| || |
+2.69 (+33.58%)since 12/27/22
| || |
+0.29 (+2.79%)since 10/27/22
| || |
-3.42 (-24.22%)since 01/27/22
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
/PRNewswire/ -- Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of...
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Major positive shifts are happening, but the field faces new headwinds too.
CMPS earnings call for the period ending September 30, 2022.
The company specializes in developing psychedelics as therapies.
COMPASS Pathways PLC Sponsored ADR (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
|Compass Pathways Plc ADR|
|Advisorshares Psychedelics ETF|
|Ark Genomic Revolution ETF|
|Virtus Lifesci Biotech Clinical Trials ETF|
|Alps Medical Breakthroughs ETF|
|Nasdaq Biotechnology Ishares ETF|
|3rd Resistance Point||11.15|
|2nd Resistance Point||11.03|
|1st Resistance Point||10.87|
|1st Support Level||10.59|
|2nd Support Level||10.47|
|3rd Support Level||10.31|